Will US Drug Pricing Politics Change Intimidation Practices Globally? 05/03/2019 by Intellectual Property Watch 2 Comments Fifa Rahman writes: The global health world, particularly as concerns skyrocketing drug prices and patent abuse, is in a unique space in time. Recently, the Office of the United States Trade Representative (USTR) has been carrying on as per usual. It has threatened the Malaysian and Colombian governments at numerous junctures to prevent them from issuing compulsory licences – a completely legal mechanism which the US uses regularly – to access generic hepatitis C drugs. The Trump Administration has sent delegations to global health agencies in Geneva to intimidate them into reducing, or hiding, work on TRIPS flexibilities and fairer drug pricing.
WHO Report Shows Global Progress On Influenza Preparedness Response 18/12/2018 by David Branigan, Intellectual Property Watch Leave a Comment The World Health Organization has released a new report showing that significant progress has been made to build national and global preparedness for future influenza pandemics. This progress resulted from the collaborative multi-sectoral implementation of a WHO plan, funded by the benefit-sharing contributions of industry partners, to strengthen global health security against pandemic influenza.
Extended Monopolies On Biologic Drugs – A Warning To Developing Countries 10/09/2018 by Intellectual Property Watch Leave a Comment Historically, the US has been the primary demandeur of maximalist IP norms in FTAs. Pharmaceutical IP is market-driven, and this is no different for biologic drugs, which dominate the list of bestselling drugs worldwide, making them important economic commodities. Developing country governments must take note of the US pushing for biologics exclusivity through NAFTA as this signifies an effort to change norms worldwide.
Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 by Catherine Saez, Intellectual Property Watch 14 Comments Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries, civil society organised itself to increase access to sofosbuvir for millions in need.
Panel: E-Commerce Crucial For Development, Some Eager To Negotiate At WTO 18/04/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment The United Nations Conference on Trade and Development (UNCTAD) and its annual weeklong event focused on electronic commerce inspired a group of World Trade Organization members to launch a roadmap for e-commerce last year. This week, at the start of the fourth UNCTAD E-Commerce Week, a panel commented on the importance of e-commerce discussions at the World Trade Organization, even as some of the WTO membership disagrees on a new negotiating mandate.
Global Fund Chooses Former UK Banker Peter Sands As New Director 14/11/2017 by William New, Intellectual Property Watch Leave a Comment The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria today selected Peter Sands, a former bank CEO who is involved in health projects at the World Bank and elsewhere, as its next executive director.
Malaysia Grants Compulsory Licence For Generic Sofosbuvir Despite Gilead Licence 15/09/2017 by Catherine Saez, Intellectual Property Watch 6 Comments A much cheaper version of a groundbreaking hepatitis C medicine is expected to be available soon for the hundreds of thousands of hepatitis C patients in Malaysia, as it decided to grant a compulsory licence to sofosbuvir, according to sources. The decision comes right after the medicine originator decided to expand its voluntary licensing scheme to four more countries, including Malaysia. [Updated]
Malaysia Inclusion In Gilead Voluntary Licence – A Product Of Compulsory Licence Pressure 24/08/2017 by Intellectual Property Watch 3 Comments Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug. The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug.
Group of Eight Developing Islamic Countries (D-8) Approve Ten Year Roadmap 10/07/2008 by Wagdy Sawahel for Intellectual Property Watch Leave a Comment By Wagdy Sawahel for Intellectual Property Watch Leaders of the Group of Eight Developing Islamic Countries (D-8) this week adopted an ambitious 10-year blueprint to substantially expand trade and economic cooperation with the aim of improving the position of Muslim developing countries in the global world economy, according to the Kuala Lumpur declaration on meeting […]